Investors & News
Corporate ProfileImago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of blood cancers. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. The company is advancing the clinical development of its first internally discovered LSD1 inhibitor, bomedemstat, for the treatment of myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating bomedemstat in three Phase 2 clinical studies for essential thrombocythemia (ET), myelofibrosis (MF) and polycythemia vera (PV). Learn more about our clinical pipeline here. The company is based in South San Francisco, California.
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
Data Provided by Refinitiv. Minimum 15 minutes delayed.